Medi Caps

Who are the top shareholders of the Medi Caps?

The top shareholders of Medi Caps include Alok K Garg, who holds 25.87%, and individual investors with a combined 44.57%. The highest public shareholder is Sangeetha S at 5.57%, with no pledged promoter holdings and minimal mutual fund or foreign institutional investor involvement.

The top shareholders of Medi Caps include the promoters, with Alok K Garg holding the highest stake at 25.87%. Individual investors collectively hold 44.57% of the shares, while the highest public shareholder is Sangeetha S, who owns 5.57%. Additionally, there are no pledged promoter holdings, and the company has minimal mutual fund and foreign institutional investor involvement.

how big is Medi Caps?

As of October 2023, Medi Caps Ltd has a market capitalization of 53.55 Cr, classified as a Micro Cap, with recent net sales of 25.48 Cr and a net profit of -0.58 Cr over the last four quarters. Shareholder's funds are 120.98 Cr, and total assets are 127.28 Cr as of March 2024.

Market Cap: Medi Caps Ltd has a market capitalization of 53.55 Cr and is classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters, which includes the periods of Mar'25, Dec'24, Sep'24, and Jun'24, is 25.48 Cr. The sum of Net Profit for the same quarters is -0.58 Cr. This data is presented on a Consolidated basis.<BR><BR>Balance Sheet Snapshot: This is also on a Consolidated basis for the latest annual period ending in Mar'24. Shareholder's Funds are reported at 120.98 Cr, while Total Assets amount to 127.28 Cr.

Who are in the management team of Medi Caps?

As of March 2023, the management team of Medi Caps includes R C Mittal (Chairman), Alok K Garg (Managing Director), and several non-executive and independent directors, along with a Company Secretary. The team features a diverse mix of executive and non-executive roles.

As of March 2023, the management team of Medi Caps includes the following individuals:<BR><BR>1. R C Mittal - Chairman (Non-Executive)<BR>2. Alok K Garg - Managing Director<BR>3. Pramod Fatehpuria - Non-Executive & Independent Director<BR>4. Ashok Omprakash Agrawal - Non-Executive & Independent Director<BR>5. Kusum Mittal - Non-Executive Director<BR>6. Dharmendra Solanki - Independent Director<BR>7. Abhishek Kumar - Company Secretary & Compliance Officer<BR>8. Gajendra Singh - Independent Director<BR><BR>This team comprises a mix of executive and non-executive directors, along with a compliance officer.

When is the next results date for Medi Caps?

No Upcoming Board Meetings

What is the bonus history of the Medi Caps?

Medi Caps issued a 3:1 bonus in 2013, where shareholders received three additional shares for each share held. The ex-date was March 19, 2013, and the record date was March 20, 2013.

Medi Caps has a bonus history that includes a significant bonus issue announced in 2013. Specifically, the company issued a 3:1 bonus, which means that for every one share held, shareholders received three additional shares. The ex-date for this bonus was March 19, 2013, and the record date was March 20, 2013. This was the latest recorded bonus action for the company.

Has Medi Caps declared dividend?

Medi Caps Ltd has declared a 15% dividend, amounting to 0.3800 per share, but the dividend yield is 0% as no recent dividends have been paid out. Total returns have varied significantly, with a 333.3% increase over the past 5 years despite negative returns in shorter periods.

Medi Caps Ltd has declared a 15% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 15%<BR>- Amount per share: 0.3800<BR>- Ex-date: 20 Sep 12<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -17.38%, the dividend return was 0%, resulting in a total return of -17.38%.<BR><BR>In the 1-year period, the price return was -5.29%, the dividend return was 0%, resulting in a total return of -5.29%.<BR><BR>In the 2-year period, the price return was 18.03%, the dividend return was 0%, resulting in a total return of 18.03%.<BR><BR>In the 3-year period, the price return was -13.68%, the dividend return was 0%, resulting in a total return of -13.68%.<BR><BR>In the 4-year period, the price return was -7.57%, the dividend return was 0%, resulting in a total return of -7.57%.<BR><BR>In the 5-year period, the price return was 333.3%, the dividend return was 0%, resulting in a total return of 333.3%.<BR><BR>Overall, while Medi Caps has declared a dividend, the dividend yield remains at 0%, indicating no recent dividends have been paid out. The total returns show significant volatility, with a notable increase over the 5-year period despite negative returns in shorter time frames.

Is Medi Caps overvalued or undervalued?

As of February 9, 2024, Medi Caps is considered undervalued with a low Price to Book Value of 0.44 and a negative PE Ratio of -53.55, despite its recent stock performance showing a YTD return of -10.77%, indicating a significant shift from a very expensive to a risky valuation grade compared to peers like Sun Pharma and Divi's Lab.

As of 9 February 2024, Medi Caps has moved from a valuation grade of very expensive to risky, indicating a significant shift in its financial outlook. The company is currently assessed as undervalued, primarily due to its low Price to Book Value of 0.44 and a negative PE Ratio of -53.55. Other notable ratios include an EV to EBITDA of -13.35 and a ROCE of -3.85%, which further highlight the company's struggles.<BR><BR>When compared to its peers, Medi Caps stands out with a PEG Ratio of 0.00, while competitors like Sun Pharma and Divi's Lab have significantly higher PE Ratios of 35.25 and 79.33, respectively. This stark contrast suggests that Medi Caps may be undervalued relative to its peers, despite its current financial challenges. Additionally, the company's recent stock performance shows a YTD return of -10.77%, underperforming against the Sensex, which returned 5.62% in the same period.

What is the technical trend for Medi Caps?

As of June 4, 2025, Medi Caps shows a mildly bearish technical trend, with mixed signals from the MACD and bearish indicators from moving averages and Bollinger Bands.

As of 4 June 2025, the technical trend for Medi Caps has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, but the monthly MACD is mildly bearish, indicating mixed signals. The Bollinger Bands are bearish in both weekly and monthly time frames, and daily moving averages are also bearish. The KST shows a mildly bullish stance on the weekly chart but is mildly bearish on the monthly. There are no clear trends indicated by Dow Theory in either time frame. Overall, the current technical stance is mildly bearish, driven primarily by the bearish signals from moving averages and Bollinger Bands, despite some mildly bullish indicators in the MACD and KST on the weekly chart.

Who are the peers of the Medi Caps?

Medi Caps' peers include Vasundhara Rasy., Vivo Bio Tech, Concord Drugs, Lasa Supergeneri, Dipna Pharmachem, Shelter Pharma, Transchem, Sandu Pharma, and Kabra Drugs. Medi Caps has average management risk and a 1-year return of -9.65%, higher than Vasundhara Rasy.'s -29.95% but lower than other peers.

Peers: The peers of Medi Caps are Vasundhara Rasy., Vivo Bio Tech, Concord Drugs, Lasa Supergeneri, Dipna Pharmachem, Shelter Pharma, Transchem, Sandu Pharma., and Kabra Drugs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Shelter Pharma, while Average management risk is found at Medi Caps, Vasundhara Rasy., Vivo Bio Tech, and Transchem. Below Average management risk is present at Concord Drugs, Lasa Supergeneri, Dipna Pharmachem, Sandu Pharma., and the rest. Growth is Excellent at Dipna Pharmachem, Good at Shelter Pharma, Average at Medi Caps, Vasundhara Rasy., Vivo Bio Tech, and Transchem, and Below Average at Concord Drugs, Lasa Supergeneri, Sandu Pharma., and the rest. Capital Structure is Excellent at Shelter Pharma, Good at Medi Caps and Vasundhara Rasy., Average at Lasa Supergeneri, and Below Average at Vivo Bio Tech, Concord Drugs, Dipna Pharmachem, Transchem, Sandu Pharma., and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Dipna Pharmachem at 203.59%, while the lowest is Vasundhara Rasy. at -29.95%. Medi Caps has a 1-year return of -9.65%, which is higher than Vasundhara Rasy. but lower than the rest. Additionally, the peers with negative six-month returns include Lasa Supergeneri, Shelter Pharma, and Medi Caps.

What does Medi Caps do?

Medi Caps Ltd is a micro-cap pharmaceutical company that manufactures empty hard gelatine capsules for oral medications. As of March 2025, it reported net sales of 70 Cr and a net profit of 17 Cr, with a market cap of INR 56 Cr.

Overview: <BR>Medi Caps Ltd is a micro-cap company in the Pharmaceuticals & Biotechnology industry, specializing in the manufacturing of empty hard gelatine capsules for dosaged medicines intended for oral administration.<BR><BR>History: <BR>Medi Caps was incorporated in August 1983 as a private limited company and transitioned to a public limited company in March 1986. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>- Net Sales: 70 Cr (Quarterly Results - Mar 2025) <BR>- Net Profit: 17 Cr (Quarterly Results - Mar 2025) <BR>- Market cap: INR 56 Cr (Micro Cap) <BR><BR>Key Metrics: <BR>- P/E: N/A <BR>- Industry P/E: 37 <BR>- Dividend Yield: 0.00% <BR>- Debt Equity: -0.24 <BR>- Return on Equity: -0.48% <BR>- Price to Book: 0.46 <BR><BR>Contact Details: <BR>Address: Mhow-Neemuch Road, Sector - I Pithampur Madhya Pradesh : 454775 <BR>Tel: 91-07292-424242 <BR>Email: investors@medicaps.com <BR>Website: http://www.medicaps.com

Are Medi Caps latest results good or bad?

Medi Caps' latest results are poor, with a significant decline in key metrics: Profit Before Tax fell to Rs -3.82 crore, and Profit After Tax dropped to Rs -3.49 crore, alongside a 31.34% decrease in net sales year-on-year. Overall, the company is facing substantial financial challenges.

Medi Caps has reported disappointing financial results for the quarter ending June 2025. The company experienced a significant decline in key metrics, indicating a challenging period. <BR><BR>Profit Before Tax (PBT) fell to Rs -3.82 crore, a drastic decrease of 325.6% compared to the average PBT of the previous four quarters. Similarly, Profit After Tax (PAT) dropped to Rs -3.49 crore, reflecting a staggering decline of 2306.9% from prior averages. <BR><BR>Net sales for the last six months reached Rs 9.66 crore, showing a year-on-year decrease of 31.34%. The operating profit also hit a low of Rs -3.37 crore, marking the lowest performance in the last five quarters, with an operating profit margin recorded at 0.00%. Additionally, earnings per share (EPS) fell to Rs -2.80, highlighting the ongoing challenges in achieving profitability.<BR><BR>Overall, these results suggest that Medi Caps is facing significant difficulties, and the performance can be characterized as poor.

How has been the historical performance of Medi Caps?

Medi Caps has experienced a significant decline in net sales and profitability, with net sales dropping from 69.87 Cr in Mar'22 to 25.47 Cr in Mar'25, resulting in operating losses and negative profits over the same period. The company's total assets also decreased slightly, reflecting ongoing financial challenges.

Answer:<BR>The historical performance of Medi Caps shows a significant decline in net sales and profitability over the years, culminating in losses in the most recent fiscal year.<BR><BR>Breakdown:<BR>Medi Caps experienced a downward trend in net sales, dropping from 69.87 Cr in Mar'22 to 25.47 Cr in Mar'25. This decline is mirrored in total operating income, which also fell from 69.87 Cr in Mar'22 to 25.47 Cr in Mar'25. The company's total expenditure, excluding depreciation, decreased from 59.92 Cr in Mar'22 to 27.30 Cr in Mar'25, yet this was not sufficient to prevent operating losses, with operating profit (PBDIT) declining from 11.86 Cr in Mar'22 to -1.83 Cr in Mar'25. Profit before tax also turned negative, moving from 10.06 Cr in Mar'22 to -0.84 Cr in Mar'25, and profit after tax followed suit, decreasing from 10.04 Cr in Mar'22 to -0.57 Cr in Mar'25. The company's cash flow from operating activities showed a slight decrease from 7.00 Cr in Mar'22 to 5.00 Cr in Mar'25, while total assets slightly decreased from 130.35 Cr in Mar'22 to 125.42 Cr in Mar'25. Overall, Medi Caps has faced significant challenges, reflected in its declining sales, profitability, and asset values over the past few years.

Should I buy, sell or hold Medi Caps?

Which are the latest news on Medi Caps?

Why is Medi Caps Ltd falling/rising?

As of 18-Jan, Medi Caps Ltd's stock price is declining, currently at Rs 31.00, reflecting a significant drop due to poor financial performance, including a 47.76% decline in net sales and negative profitability. The company's weak fundamentals and reduced investor interest are contributing to its underperformance in the market.

As of 18-Jan, Medi Caps Ltd's stock price is falling, currently at Rs 31.00, which reflects a decrease of Rs 2.0 or 6.06%. The stock has underperformed its sector by 4.95% today and has experienced significant volatility, with an intraday low of Rs 29.6, marking a decline of 10.3%. <BR><BR>The company's recent financial performance has been troubling, with a reported net sales decline of 47.76% over the last nine months and a negative profit after tax of Rs -1.82 crore, which is a drastic fall of 107.4% compared to the previous four-quarter average. Additionally, the company has a weak ability to service its debt, indicated by a poor EBIT to interest ratio of -1.38, and a low return on equity of 1.46%, suggesting low profitability.<BR><BR>Over the past year, Medi Caps Ltd has generated a return of -37.50%, significantly underperforming the benchmark Sensex, which has increased by 8.47% during the same period. This consistent underperformance over the last three years, coupled with operating losses and a negative EBITDA, contributes to the stock's declining price. Furthermore, there has been a notable decrease in investor participation, with delivery volume dropping by 77.86% against the five-day average, indicating reduced interest in the stock.<BR><BR>Overall, the combination of poor financial results, weak fundamentals, and declining investor confidence are the primary reasons for the falling stock price of Medi Caps Ltd.